Friday, May 31, 2019 Daily Archives

Manufacturing Considerations for Virus Filtration Processes Using Planova BioEX

by

This webcast features: Parag Patel, Senior Regional Manager, Asahi Kasei Bioprocess Viral clearance of biopharmaceutical- and plasma-derived therapeutics is an important regulatory requirement that ensures patient safety.  Although there are many viral clearance strategies and technologies that can be deployed, size exclusion filtration remains the gold standard in virus removal. Virus filtration by size exclusion is a robust method for removing virus without impacting the efficacy of the final drug product.  We will take you through the steps of developing…

May 31, 2019

Developability: Evaluating Specificity, Immunogenicity, Functionality, and Manufacturability for Lead Candidate Selection

by

This webcast features: Campbell Bunce, Chief Scientific Officer, Abzena Developability assessment is based on multiple readouts that capture the fundamental characteristics of successful drug design: specificity, functionality, safety and manufacturability. Developability assessment can severely reduce the time and expenditure required to take multiple lead candidates through expensive cell line development and manufacturing runs when the molecule has inherent liabilities that will inhibit its progress. Why do it: Identify liabilities and risk factors in drug candidates early in the development process…

May 31, 2019